ELOVL2 and neoplasm: ESR1-YAP1 cistromic-transcriptomic overlap also revealed enrichment of ELOVL2, a tumor suppressor in tamoxifen-resistant settings, which emphasizes the need for further investigation in how tumor suppressors may be functioning in fusion-dependent contexts (65).